To put it plainly, the cost of Radicava is high. Infusions are $1,000 per treatment and a full year of treatment can add up to $146,000.
“One of the things that was a really important goal is to make and ensure Radicava is accessible to people with ALS,” said Larson.
“We plan to have a very generous program where we plan to remove as best we can the barriers to access as it relates to out of pocket expenses,” added Randy McGonigal, the M.T. Pharama America director of market.
McGonigal said they have a program called “Searchlight Support” that will help patients access the drug. In some cases, he said, uninsured or under-insured patients may not be charged at all.
Given all the variables, McGonigal said he can’t say exactly how much the average person will pay out of pocket.
“It's hard to say, here's exactly how we are going to help every single patient, because you're right, it varies so wildly,” McGonigal said.
ALS advocacy organization Team Gleason said while Radicava is not a cure, it is a step in the right direction.
"The data shows Radicava can slow the progression in those recently diagnosed. Although the affect is said to be modest, it is more than was previously available. And for people with ALS, that’s incredible news,” a spokesperson wrote in a release.
"What does it mean to the average patient?” asked Denton. “I think if you can afford it, I think you should take it."